2015台灣生技月 Bio Taiwan 生物科技大展

2015 台灣生技月 南港展覽館

ABOUT

Why Attend BioTaiwan

Taiwan Economy and Biotech Industry Ranked High Globally

  1. Investment Risk #3 (BERI)
  2. Entrepreneurship #7, #1 Asia (GEDI)
  3. Global Competitiveness #13 (IMD)
  4. Higher Education #12 (WEF)
  5. Innovation Capability #10 (WEF)
  6. Knowledge Based Economy #13, #1 Asia (World Bank)
  7. Scientific American Biotech Global Ratings
    • - Overall Competitiveness #17
    • - Enterprise Support #6
    • - Intensity #9
    • - Foundation #1
    • - Market Cap #3 (after US, Australia)

Network with top executives, investors, experts and renown leaders from Taiwan, China, and beyond
Exhibit bioclusters, technologies, unique products and services
Discover biopharma innovations in Taiwan and Asia
Capture Greater China and Asia’s biotech market opportunities through Taiwan
Explore R&D, products, services and new partnerships

Taiwan’s biotech industry market value has reached 900bil TWD (30bil USD) and will soon approach its first trillion TWD as Taiwan becomes an integral part of the global biopharma industry chain. The government’s initiatives to support Taiwan's biotech development and innovation are critical for continued strong growth momentum. BioBuisness Asia explores such investment opportunities in Taiwan. The event takes an in-depth look at issues regarding bio-investing and future trends in biomedical and life sciences within the Asia region. In 2016, the BioTaiwan exhibition had a record number of participants, reaching a total of 605 exhibitors, 1,305 booths, and 100,786 plus visitors representing Taiwan, Japan, Korea, China, India, North America and countries from the European Union.

Superior Strengths of Taiwan's Biotech Industry

  1. Vibrant VC and capital market
  2. Solid innovation pipeline
  3. World-class clinical trial capabilities
  4. Strong IP protection and enforcement
  5. Transparent legal and business practices
  6. Highly-educated and motivated workforce
  7. Strong government support
  8. Executives with overseas experience and global view
  9. Ideal strategic partner for entering the Greater China market